Reports Q4 revenue $1.5M, consensus $1.94M. “Werewolf made considerable progress in 2023, setting up 2024 as a year of execution across our pipeline,” said Daniel J. Hicklin, Ph.D., President and Chief Executive Officer of Werewolf. “In the first half of this year, we plan to present additional clinical data from our Phase 1/1b clinical trial of WTX-124, including updated monotherapy data and initial combination data, which we anticipate will build on the promising signals of antitumor activity and improved therapeutic index that we observed in the data presented at SITC last year. In addition, we plan to share data further demonstrating the performance of our platform in our preclinical programs at AACR. We also plan to share initial clinical data from WTX-330, our second clinical candidate, in the second quarter of 2024.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on HOWL:
- Werewolf Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Werewolf Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2024
- Werewolf Therapeutics Expands Offering with $25M Stock Sale
- Werewolf Therapeutics Provides Business Update and Highlights 2024 Strategic Outlook
- Werewolf Therapeutics provides business update, highlights 2024 outlook